ClinicalTrials.gg
CompletedNCT06292910VACO2Updated Mar 5, 2024

Central Venous to Arterial CO2 Difference and Low Cardiac Output Syndrome Related Outcomes in Children After Cardiac Surgery

An observational study in Congenital Heart Disease, Perioperative/Postoperative Complications and Lactate Blood Increase, sponsored by Prince of Songkla University. Completed at 1 site in Thailand. Open to participants aged 1 Day to 18 Years. Per ClinicalTrials.gov, last updated 2024-03-05.

Sponsored by Prince of Songkla University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
136
Ages
1 Day to 18 Years
Sex
All
01

Study summary

The goal of this clinical trial is to compare the capability of 3 different bedside surrogates in children who underwent cardiac surgery and were admitted in intensive care unit. These test are lactate, oxygen saturation from central venous and the carbon dioxide gap between central venous and arterial.

The main questions is which one is the best prognostication for post operation poor outcomes Participants will be taken routine blood test for post cardiac care (at ICU arrival, 6, 12, and 24 hour post operation) and follow the their outcomes. There is no any intervention or drug in this research

02

Conditions studied

  • Congenital Heart Disease
  • Perioperative/Postoperative Complications
  • Lactate Blood Increase
03

In context

Heart Defects, Congenital

991 studies on the registry are indexed under Heart Defects, Congenital; 251 are open to participants now.

This study's enrollment of 136 is above the median of 119 across 440 observational studies indexed under Heart Defects, Congenital.

Browse Heart Defects, Congenital studies →

Lead sponsor

Prince of Songkla University is the lead sponsor of 116 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Day to 18 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Children with cardiac disease in Songklanagarind hospital who undergone open cardiac surgery with cardiopulmonary bypass (age \< 18 years old)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 0-18 years old with either congenital or acquired cardiac disease
  • Undergone cardiopulmonary bypass for cardiac surgery
  • Be admitted in PICU for post-operative care

Exclusion criteria

Exclusion Criteria:

  • Preterm infant (GA \< 37 weeks) or weight less than 2 kg
  • Patient who weaned off cardiopulmoanry bypass and required extracorporeal membrane oxygenator (ECMO) before leaving the operating room
  • Patient who required emergency cardiac operation within 24 hour after hospitalization
  • Patient who had significant residual left side outflow tract obstruction (e.g., coarctation of aorta, interrupted aortic arch) which defined by difference of SBP between upper and lower extremities more than 10 mmHg
  • Patient who had already participated in another research project
  • Patient who does not have both arterial line and central line catheter back from operating room
  • Parents or legal guardian refuse to inform consent.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
136 participants (actual)
Patient registry
No

Interventions

  • Diagnostic testarterial and central venous blood gas analysis, lactate

    blood gas analysis

06

What researchers measure

Primary outcomes

  1. number of participant who developed low cardiac output syndrome related poor outcomes within 24 hour post operation

    the low cardiac output syndrome (LCOS) related poor outcomes was diagnosed if at least two of the following criteria were met within 24 hours postoperatively: 1. clinical LCOS: prolonged capillary refill \>3 seconds, systolic blood pressure \<5th percentile for age and sex, persistent elevation of left atrial pressure \>10 mmHg for at least 6 hours, and low urinary output (\<1 mL/kg/hour) for at least 6 hours despite diuretic use 2. laboratory LCOS: persistently elevated lactate level (\>2 mmol/L), metabolic acidosis with an increase in the base deficit (\>4 mmol/L) for at least 6 hours consecutively 3. Vasoactive-inotropic score ≥20 4. any unplanned surgery or intervention, cardiac arrest, or utilization of ECMO 5. left ventricular fraction \<50% on echocardiography

    Time frame: from time of subject was admitted to ICU until the 24 hour post operation

Secondary outcomes

  1. ventilator days

    number of the days subject was intubated and used mechanical ventilator after operation

    Time frame: from date of subject was admitted to ICU until the date of subject was extubated, assessed up to 28 days

  2. inotrope days

    number of the days subject was on inotropic medication after operation

    Time frame: from date of subject was admitted to ICU until the date of subject was free of inotropic drugs, assessed up to 28 days

  3. length of stay in ICU

    number of the days subject was stay in ICU after operation

    Time frame: from date of subject was admitted to ICU until the date of subject was discharge, assessed up to 28 days

07

Study locations

1 site
  • Faculty of Medicine, Prince of Songkla University
    Hat Yai, Songkhla 90110, Thailand
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — This data might be analyzed in other project and also we need to submit the form of data sharing to local EC unit.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06292910
Responsible party
Pharsai Prasertsan (Assist. Prof, Prince of Songkla University) — Principal investigator
First posted
Mar 5, 2024
Start date
Aug 8, 2021
Primary completion
Dec 21, 2023
Completion
Dec 26, 2023
Last update
Mar 5, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion